European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension
European Respiratory Journal · 07.09.2026 · 2601178
DOI: 10.1183/13993003.01178-2026 ↗Kurz gefasst
Leitlinie in der Zeitschrift European Respiratory Journal, online erschienen am 07.09.2026. Verfasst von Gabor Kovacs und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Department of Internal Medicine, Lung Research Cluster, Medical University of Graz, Graz, Austria gabor.kovacs@unik…. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Pulmonary arterial hypertension (PAH) is a severe, progressive disease of the small pulmonary arteries. These guidelines provide updated evidence-based recommendations for the treatment of PAH focusing on the latest scientific evidence on sotatercept, an activin signalling inhibitor targeting a novel pathway for the treatment of PAH, and on the role of right heart catheterisation (RHC) in the management of PAH patients during follow-up.
Methods
A European Respiratory Society (ERS) Task Force, comprising global experts, methodologists and a patient representative, developed these clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Four PICO (Patients, Intervention, Comparator, Outcomes) questions and one narrative question have been addressed. Recommendations The Task Force recommends add-on treatment with sotatercept in PAH patients who already receive PAH drugs and are at intermediate-low, intermediate-high or high risk of death during follow-up; this recommendation is based on a high certainty of evidence available from randomised controlled trials (RCTs). In PAH patients at low risk of death, the Task Force does not provide a recommendation due to the low certainty of evidence and the limited number of such patients included in RCTs. To monitor safety and efficacy, patients receiving sotatercept should be treated in pulmonary hypertension centres and their management should include regular follow-up and appropriate examinations. To guide treatment strategy, the Task Force suggests performing RHC during follow-up in PAH patients who receive PAH drugs and are at intermediate-low, intermediate-high or high risk of death, when therapeutic consequences are expected. The Task Force does not provide a recommendation for this question in PAH patients at low risk of death, due to the very low certainty of evidence.
Conclusion
The ERS guidelines on the treatment of PAH provide an updated evidence-based framework for the optimal management of patients with PAH.
Autor:innen und Institutionen
- Division of Respiratory Medicine, Department of Internal Medicine, Lung Research Cluster, Medical University of Graz, Graz, Austria gabor.kovacs@uniklinikum.kages.at.
- Division of Respiratory Medicine, Department of Internal Medicine, Lung Research Cluster, Medical University of Graz, Graz, Austria.
- Institute of Health Computing, University of Maryland, Bethesda, MD, USA.
- Division of Respiratory, Critical Care and Sleep Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
- Université Paris-Saclay, Inserm UMR_S 1358 (HPPIT), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre (AP-HP), European Reference Network for Rare Respiratory Diseases (ERN-LUNG), Le Kremlin-Bicêt…
- Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.
ORCID-Profile: Katarina Zeder, Marc Humbert, Robin Condliffe, Athenais Boucly, Peter Dorfmüller, George Giannakoulas, Sergio Harari, Nicole Ngai Yung Tsang, Rozenn Quarck, Olivier Sitbon, Anton Vonk Noordegraaf, Lan Zhao, Marius Hoeper, Marion Delcroix
Zitieren
APA
Kovacs, G., Zeder, K., Humbert, M., Condliffe, R., Toews, I., Boucly, A., Aldred, M., Badagliacca, R., Chung, W., De Man, F., Dorfmüller, P., Ferrari, P., Giannakoulas, G., Harari, S., Kotsimbos, T., Tsang, N. N. Y., Quarck, R., Rodrigues, A., Rosenkranz, S., …, & Delcroix, M. (2026). European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension. European Respiratory Journal, 2601178. https://doi.org/10.1183/13993003.01178-2026
Vancouver
Kovacs G, Zeder K, Humbert M, Condliffe R, Toews I, Boucly A, et al. European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension. European Respiratory Journal. 2026:2601178. doi:10.1183/13993003.01178-2026
BibTeX
@article{Kovacs2026,
author = {Kovacs, Gabor and Zeder, Katarina and Humbert, Marc and Condliffe, Robin and Toews, Ingrid and Boucly, Athenais and Aldred, Micheala and Badagliacca, Roberto and Chung, Wendy and De Man, Frances and Dorfmüller, Peter and Ferrari, Pisana and Giannakoulas, George and Harari, Sergio and Kotsimbos, Tom and Tsang, Nicole Ngai Yung and Quarck, Rozenn and Rodrigues, Antenor and Rosenkranz, Stephan and Sitbon, Olivier and Vonk Noordegraaf, Anton and Zhao, Lan and Hoeper, Marius and Delcroix, Marion},
title = {European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension},
journal = {European Respiratory Journal},
year = {2026},
pages = {2601178},
doi = {10.1183/13993003.01178-2026}
}
EUVIMED